caffeine treatment parkinson disease abstract objective epidemiologic studies consistently link caffeine nonselective adenosine antagonist lower risk parkinson disease pd symptomatic effects caffeine pd adequately evaluated methods conducted num week randomized controlled trial caffeine pd assess effects daytime somnolence motor severity nonmotor features patients pd daytime somnolence epworth num caffeine num mg daily num weeks num mg daily num weeks matching placebo primary outcome epworth sleepiness scale score secondary outcomes included motor severity sleep markers fatigue depression quality life effects caffeine analyzed bayesian hierarchical models adjusting study site baseline scores age sex results num patients num randomized placebo num caffeine primary intention-to-treat analysis caffeine resulted nonsignificant reduction epworth sleepiness scale score num points num confidence interval ci num num somnolence improved clinical global impression change num num num intention-to-treat significant reduction epworth sleepiness scale score per-protocol analysis num num num caffeine reduced total unified parkinson's disease rating scale score num points num num objective motor component num points num num modest improvement global health measures quality life depression sleep quality adverse events comparable caffeine placebo groups conclusions caffeine provided equivocal borderline improvement excessive somnolence pd improved objective motor measures potential motor benefits suggest larger long-term trial caffeine warranted classification evidence study class evidence caffeine num mg bid num weeks significant benefit excessive daytime sleepiness patients pd 
